
Join to View Full Profile
- 1493 Cambridge StCambridge Health AllianceCambridge, MA 02139 
- Phone+1 617-665-2300 
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jan Hillson, MD is a rheumatologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Washington.
Education & Training
 University of WashingtonFellowship, Rheumatology, 1986 - 1989 University of WashingtonFellowship, Rheumatology, 1986 - 1989
 University of WashingtonResidency, Internal Medicine, 1982 - 1983 University of WashingtonResidency, Internal Medicine, 1982 - 1983
![University of Washington [Boise]](https://doximity-res.cloudinary.com/image/upload/t_public_profile_badge_image/v1611270202/logos/eed74718-1bf2-41cb-8ff9-b588306e78e9.png) University of Washington [Boise]Residency, Internal Medicine, 1981 - 1982 University of Washington [Boise]Residency, Internal Medicine, 1981 - 1982
 University of WashingtonInternship, Internal Medicine, 1980 - 1981 University of WashingtonInternship, Internal Medicine, 1980 - 1981
 Stanford University School of MedicineClass of 1980 Stanford University School of MedicineClass of 1980
Certifications & Licensure
 WA State Medical License 1981 - 2026 WA State Medical License 1981 - 2026
 American Board of Internal Medicine Internal Medicine American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 12 citationsFirst-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjectsJing Yang, Jason D. Lickliter, Jan Hillson, Gary Means, Russell J. Sanderson
 Clinical and Translational Science. 2021-07-01
- 38 citationsEvaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomi...Peter A. Merkel, David Jayne, Chao Wang, Jan Hillson, Pirow Bekker
 JMIR Research Protocols. 2020-04-07
- 20 citationsMolecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.Victor Farutin, Thomas Prod’homme, Kevin Mcconnell, Nathaniel Washburn, Patrick Halvey
 Arthritis Research & Therapy. 2019-10-23
Press Mentions
 Great Danes: Two Nordic Biotechs Name Their Chief Executives; Axel Hoos Bids Adieu to GlaxoSmithKline, Becomes CEO of Small Oncology PlayerJuly 9th, 2021 Great Danes: Two Nordic Biotechs Name Their Chief Executives; Axel Hoos Bids Adieu to GlaxoSmithKline, Becomes CEO of Small Oncology PlayerJuly 9th, 2021
 Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to Its Board of DirectorsJuly 2nd, 2021 Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to Its Board of DirectorsJuly 2nd, 2021
 Alpine Immune Sciences (ALPN) Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at ASHDecember 9th, 2019 Alpine Immune Sciences (ALPN) Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at ASHDecember 9th, 2019
- Join now to see all









